A retrospective study of over 30,000 US adults aged ≥65 found no significant difference in flu prevention between adjuvanted (aQIV) and high-dose (HD-QIV) quadrivalent influenza vaccines during the 2022-2023 season.
Rates of test-confirmed influenza were similar for both vaccine groups across all hospital settings.
Findings support Advisory Committee on Immunization Practices (ACIP) recommendations to use either vaccine in older adults.
